WordNet

use recreational drugs (同)do drugs
administer a drug to; "They drugged the kidnapped tourist" (同)dose
a substance that is used as a medicine or narcotic
relating to or involved in therapy; "therapeutic approach to criminality" (同)therapeutical
branch of medicine concerned with the treatment of disease
the act of observing something (and sometimes keeping a record of it); "the monitoring of enemy communications plays an important role in war times"

PrepTutorEJDIC

『薬』,薬品,薬剤 / 『麻薬』,麻酔剤 / 〈人〉‘に'薬(特に麻酔剤)を与える / 〈飲食物〉‘に'(麻酔薬・毒薬などの)薬を混ぜる
治療[上]の
治療学

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/05/19 14:28:09」(JST)

wiki en

Therapeutic drug monitoring (TDM) is a branch of clinical chemistry and clinical pharmacology that specializes in the measurement of medication concentrations in blood. Its main focus is on drugs with a narrow therapeutic range, i.e. drugs that can easily be under- or overdosed.^[1] TDM aims at improving patient care by individually adjusting the dose of drugs for which clinical experience or clinical trials have shown it improved outcome in the general or special populations. It can be based on a priori pharmacogenetic, demographic and clinical information, and/or on the a posteriori measurement of blood concentrations of drugs (pharmacokinetic monitoring) or biological surrogate or end-point markers of effect (pharmacodynamic monitoring).^[2]

There are numerous variables that influence the interpretation of drug concentration data: time, route and dose of drug given, time of blood sampling, handling and storage conditions, precision and accuracy of the analytical method, validity of pharmacokinetic models and assumptions, co-medications and, last but not least, clinical status of the patient (i.e. disease, renal/hepatic status, biologic tolerance to drug therapy, etc.).^[3]

Many different professionals (physicians, clinical pharmacologists, clinical pharmacists, nurses, medical laboratory scientists, etc.) are involved with the various elements of drug concentration monitoring, which is a truly multidisciplinary process. Because failure to properly carry out any one of the components can severely affect the usefulness of using drug concentrations to optimize therapy, an organized approach to the overall process is critical.^[3]

A priori therapeutic drug monitoring

“

A priori TDM consists of determining the initial dose regimen to be given to a patient, based on clinical endpoint and on established population pharmacokinetic-pharmacodynamic (PK/PD) relationships. These relationships help to identify sub-populations of patients with different dosage requirements, by utilizing demographic data, clinical findings, clinical chemistry results, and/or, when appropriate, pharmacogenetic characteristics.

”

—IATDMCT Executive Committee, Definition of TDM^[2]

A posteriori therapeutic drug monitoring

“

includes pre-analytical, analytical and post-analytical phases, each with the same importance;
is most often based on the specific, accurate, precise and timely determinations of the active and.or toxic forms of drugs in biological samples collected at the appropriate times in the correct containers (PK monitoring), or can employ the measurement of a biological perimeter as a surrogate or end-point marker of effect (PD monitoring) e.g. concentration of an endrogenous compound, enzymatic activity, gene expression, etc. either as a complement to PK monitoring or as the main TDM tool;
requires interpretation of the results, taking into account pre-analytical conditions, clinical information and the clinical efficiency of the current dosage regimen; this can be achieved by the application of PK-PD modeling;
can potentially benefit from population PK/PD models possibly combined with individual pharmacokinetic forecasting techniques, or pharmacogenetic data.

”

—IATDMCT Executive Committee, Definition of TDM^[2]

Characteristics of drugs subject to therapeutic drug monitoring

In pharmacotherapy, many medications are used without monitoring of blood levels, as their dosage can generally be varied according to the clinical response that a patient gets to that substance. In a small group of drugs, this is impossible, as insufficient levels will lead to undertreatment or resistance, and excessive levels can lead to toxicity and tissue damage.

Indications for therapeutic drug monitoring include:

There is an experimentally determined relationship between plasma drug concentration and the pharmacological effect.
Knowledge of the drug level influences management.
There is a narrow therapeutic window
There are potential patient compliance problems.
The drug dose cannot be optimised by clinical observation alone.

Examples of drugs analysed by therapeutic drug monitoring:^[1]

Aminoglycoside antibiotics (gentamicin)
Antiepileptics (such as carbamazepine, phenytoin and valproic acid)
Mood stabilisers, especially lithium citrate
Antipsychotics (such as pimozide and clozapine)

Therapeutic drug monitoring can also detect poisoning with above drugs, should the suspicion arise.

References

^ ^a ^b Marshall WJ, Bangert SK. Clinical Chemistry, 6th Edition. Edinburgh, London: Mosby Elsevier. 2008. ISBN 978-0-7234-3455-9
^ ^a ^b ^c IATDMCT Executive Committee. "Definition of TDM", 2004, accessed July 18, 2011.
^ ^a ^b Burton ME, Shaw LM, Schentag JJ, Evans, WE. Applied Pharmacokinetics & Pharmacodynamics, 4th Edition. Baltimore, Philadelphia: Lippincott Williams & Wilkins. 2006. ISBN 978-0-7817-4431-7

External links

International Association of Therapeutic Drug Monitoring and Clinical Toxicology

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 妊娠中の臨床検査値の基準範囲 normal reference ranges for laboratory values in pregnancy
2. 成人におけるバンコマイシン投与および血清濃度のモニタリング vancomycin dosing and serum concentration monitoring in adults
3. HIVプロテアーゼ阻害剤 hiv protease inhibitors
4. アミノグリコシド aminoglycosides
5. シクロスポリンおよびタクロリムスの薬理作用および副作用 pharmacology and side effects of cyclosporine and tacrolimus

English Journal

Dynamic behaviour and residual pattern of thiamethoxam and its metabolite clothianidin in Swiss chard using liquid chromatography-tandem mass spectrometry.

Rahman MM1, Farha W1, Abd El-Aty AM2, Kabir MH1, Im SJ1, Jung DI1, Choi JH1, Kim SW1, Son YW3, Kwon CH3, Shin HC4, Shim JH5.
Food chemistry.Food Chem.2015 May 1;174:248-55. doi: 10.1016/j.foodchem.2014.11.052. Epub 2014 Nov 14.
A simultaneous method was developed to analyse thiamethoxam and its metabolite clothianidin in Swiss chard using tandem mass spectrometry (in the positive electrospray ionisation mode using multiple reaction monitoring mode) to estimate the dissipation pattern and the pre-harvest residue limit (PHRL
PMID 25529677

Electrochemical detection of protein kinase activity based on carboxypeptidase Y digestion triggered signal amplification.

Yin H1, Wang X1, Guo Y1, Zhou Y2, Ai S3.
Biosensors & bioelectronics.Biosens Bioelectron.2015 Apr 15;66:77-83. doi: 10.1016/j.bios.2014.11.014. Epub 2014 Nov 11.
An effective assay method for monitoring protein kinase activity and screening inhibitors is greatly beneficial to kinase-related drug discovery, early diagnosis of diseases, and therapeutic effect evaluation. Herein, we develop a simple electrochemical method for detecting the activity of casein ki
PMID 25460885

Vibrational spectroscopic study of polymorphism and polymorphic transformation of the anti-viral drug lamivudine.

Du Y1, Zhang H2, Xue J3, Tang W4, Fang H2, Zhang Q2, Li Y3, Hong Z2.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.Spectrochim Acta A Mol Biomol Spectrosc.2015 Feb 25;137:1158-63. doi: 10.1016/j.saa.2014.08.128. Epub 2014 Oct 7.
Vibrational spectra of hydrated and anhydrous lamivudines, and also the dynamic process of polymorphic transformation have been characterized by Fourier transform infrared (FT-IR) and Raman spectroscopic techniques. The vibrational modes of both polymorphic lamivudines are assigned. FT-IR and Raman
PMID 25305607

Japanese Journal

バンコマイシンのTDM : 腎機能正常者のMRSA感染症 (こうすれば上手くいく! 抗菌薬TDMガイドラインの実践的活用法) -- (症例からみる投与設計のポイント)

大曲貴夫,望月敬浩
月刊薬事 = The pharmaceuticals monthly 55(1), 37-42, 2013-01-00
NAID 40019548198

炎症性腸疾患に対する生物学的製剤の治療薬物モニタリング

Colombel Jean-Frederic,Feagan Brian G.,Sandborn William J. 他
Inflammatory bowel diseases : highlights from the official journal of the Crohn's & Colitis Foundation of America, Inc 3(3), 2-12, 2012-09-00
NAID 40019457425

感染症治療薬のTDM対象の拡大は必要か

松元加奈
臨床薬理 = Japanese journal of clinical pharmacology 43(4), 229-234, 2012-07-31
NAID 10030990959

Related Pictures

★リンクテーブル★

リンク元	「薬物血中濃度モニタリング」「治療薬血中濃度モニタリング」「治療薬物モニタリング」「TDM」「drug monitoring」
関連記事	「therapeutic」「therapeutics」「monitoring」「drug monitoring」「therapeutic drug」

「薬物血中濃度モニタリング」

　　[★]

英: therapeutic drug monitoring, TDM
関: 治療薬血中濃度モニタリング、治療薬物モニタリング、血中濃度モニタリング

[show details]

薬物血中濃度モニタリング TDM : 約 26,300 件
血中濃度モニタリング TDM : 約 52,600 件
治療薬血中濃度モニタリング TDM : 23 件
治療薬物モニタリング TDM : 約 22,800 件

薬物血中濃度モニタリング : 約 47,800 件
血中濃度モニタリング : 約 123,000 件
治療薬血中濃度モニタリング : 35 件
治療薬物モニタリング : 約 32,500 件